NCT01436227View on ClinicalTrials.gov

Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 17, 2012

Primary Completion Date

March 13, 2024

Study Completion Date

March 13, 2024

Conditions
Von Hippel-Lindau Syndrome
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Pazopanib Hydrochloride

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01436227 - Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome | Biotech Hunter | Biotech Hunter